Bausch Health Companies (BHC)

Bausch Health Companies Inc. (NYSE/TSX: BHC) is a global company whose mission is to improve people's lives with our health care products. We develop, manufacture and market a range of pharmaceutical, medical device and over-the-counter products, primarily in the therapeutic areas of eye health, gastroenterology and dermatology. We are delivering on our commitments as we build an innovative company dedicated to advancing global health.

Company profile

Ticker

BHC

Exchange

NYSE

Website

www.bauschhealth.com

CEO

J. Michael Pearson

Incorporated

New Jersey

Location

Quebec, Canada

Fiscal year end

Dec 31

Sector

Manufacturing > Pharmaceutical Preparation Manufacturing

Industry (SIC)

Pharmaceutical Preparations

Pfizer • Johnson & Johnson • Merck & Co • Allergan • Abbott Laboratories • Teva- Pharmaceutical Industries • Lilly(Eli) & Co • Bristol-Myers Squibb • Viatris • Abbvie ...

Former names

BIOVAIL Corp, BIOVAIL CORP INTERNATIONAL, BIOVAIL CORPORATION INTERNATIONAL, Valeant Pharmaceuticals International, Inc.

SEC CIK

0000885590

Corporate docs

Articles of Incorporation & Bylaws

Underwriting Agreements

Plans of Reorganization

Indentures

Material Contracts & Credit Agreements

Subsidiaries Lists

Subsidiaries

Bausch & Lomb Argentina S.R.L. • Waicon Vision S.A. • Bausch & Lomb (Australia) Pty Limited • Bausch Health Australia Pty Limited • Wirra Holdings Pty Limited • Bausch & Lomb Australia Holdings Pty Limited • Solta Medical Australia Pty Limited • BAUSCH HEALTH LLC • Bausch & Lomb Pharma S.A. • PharmaSwiss BH Društvo za trgovinu na veliko d.o.o. ...

BHC stock data

1M 1Y 5Y

News

From Benzinga Pro

Bausch Health to Appeal XIFAXAN Patent Decision to U.S. Court of Appeals for the Federal Circuit, Says Expects Decision To Issue Within 12-18 Months

10 Aug 22

Bausch Health Companies Inc. (TSX:BHC), and its gastroenterology business Salix Pharmaceuticals, today announced that, consistent with the company's July 28, 2022, press release, the U.S. District Court

Bausch Health Companies Shares Move Higher; Traders Circulate District Court Opinion Ruling In Favor Of Bausch Health In Xifaxan Oral Case

10 Aug 22

https://www.docdroid.com/HwXRZpa/bausch-health-vs-norwich-pharma-trial-opinion-pdf#page=2

BMO Capital Maintains Market Perform on Bausch Health Companies, Lowers Price Target to $8

10 Aug 22

BMO Capital analyst Gary Nachman maintains Bausch Health Companies (NYSE:BHC) with a Market Perform and lowers the price target from $15 to $8.

RBC Capital Maintains Sector Perform on Bausch Health Companies, Lowers Price Target to $4.5

10 Aug 22

Recap: Bausch Health Companies Q2 Earnings

9 Aug 22

Press releases

From Benzinga Pro

Bausch Health to Appeal XIFAXAN® Patent Decision to U.S. Court of Appeals for the Federal Circuit

10 Aug 22

LAVAL, Quebec, Aug. 10, 2022 /PRNewswire/ -- Bausch Health Companies Inc. (TSX:BHC), and its gastroenterology business Salix Pharmaceuticals, today announced that, consistent with the company's July 28, 2022, press

Salix Supports CMS Announcement of First ICD-10 Code for Hepatic Encephalopathy (HE)

10 Aug 22

CMS Issues New Specific ICD-10 Code K76.82 for HE LAVAL, QC, Aug. 10, 2022 /PRNewswire/ -- Bausch Health Companies Inc. (TSX:BHC) ("Bausch Health") and its gastroenterology business, Salix Pharmaceuticals,

BAUSCH HEALTH ANNOUNCES SECOND-QUARTER 2022 RESULTS

9 Aug 22

Revenues of $1.967 billionCompany to appeal anticipated court decision and vigorously defend XIFAXAN intellectual propertyBalance sheet continues to improve with early retirement of $481 million of long-term debt through

Thinking about buying stock in Toughbuilt Industries, Exela Technologies, Bausch Health, Fluence Energy, or Evofem Biosciences?

29 Jul 22

Bausch Health Provides Update Following Oral Order in XIFAXAN® Patent Litigation

28 Jul 22

Analyst ratings and price targets

Last 3 months

Average target

$8.17

Low target

$4.50

High target

$12.00

Calendar

10 May 22

12 Aug 22

31 Dec 22

Financial summary

Financial statements Chart BHC financial data

Quarter (USD)	Mar 22	Dec 21	Sep 21	Jun 21
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Annual (USD)	Dec 21	Dec 20	Dec 19	Dec 18
Revenue
Cost of revenue
Operating income
Operating margin
Net income
Net profit margin
Cash on hand
Change in cash
Diluted EPS

Cash burn rate (est.)	Burn method: Change in cash		Burn method: Operating income		Burn method: FCF (opex + capex)
	Last Q	Avg 4Q	Last Q	Avg 4Q	Last Q	Avg 4Q
Cash on hand (at last report)	2.46B	2.46B	2.46B	2.46B	2.46B	2.46B
Cash burn (monthly)	(no burn)	(no burn)	(no burn)	(no burn)	21M	(no burn)
Cash used (since last report)	n/a	n/a	n/a	n/a	92.4M	n/a
Cash remaining	n/a	n/a	n/a	n/a	2.37B	n/a
Runway (months of cash)	n/a	n/a	n/a	n/a	112.7	n/a

Beta Read what these cash burn values mean

Financial data from company earnings reports.

Recent insider trades

BHC insider ownership history Insider history

Date	Owner	Security	Transaction	Code	Indirect	10b5-1	$Price	#Shares	$Value	#Remaining
30 Jun 22	Schutter Richard U De	Common Shares, No Par Value	Grant	Acquire A	No	No	8.36	4,111	34.37K	359,590
30 Jun 22	Brett Icahn	Common Shares, No Par Value	Grant	Acquire A	No	No	8.36	3,663	30.62K	51,157
30 Jun 22	Steven D Miller	Common Shares, No Par Value	Grant	Acquire A	No	No	8.36	3,663	30.62K	101,279
30 Jun 22	Wechsler Amy B	Common Shares, No Par Value	Grant	Acquire A	No	No	8.36	822	6.87K	134,563
30 Jun 22	Robertson Russel C	Common Shares, No Par Value	Grant	Acquire A	No	No	8.36	4,560	38.12K	167,200

Data from 3, 4 and 5 filings. Values as filed, not updated for current price.

Institutional ownership, Q1 2022

BHC institutional ownership history Ownership history

0.4% owned by funds/institutions

13F holders	Current	Prev Q	Change
Total holders	2	2	–
Opened positions	0	0
Closed positions	0	1	EXIT
Increased positions	0	0
Reduced positions	1	0	NEW

13F shares	Current	Prev Q	Change
Total value	31.84M	38.48M	-17.3%
Total shares	1.39M	1.39M	-0.0%
Total puts	0	0
Total calls	0	0
Total put/call ratio	–	–	–

Largest owners	Shares	Value	Change
Bruce & Co.	1.38M	$31.56M	0.0%
LeJeune Puetz Investment Counsel	12.39K	$283K	-2.9%

Largest transactions	Shares	Bought/sold	Change
LeJeune Puetz Investment Counsel	12.39K	-364	-2.9%
Bruce & Co.	1.38M	0	0.0%

Data from 13F filings, for the last complete 13F reporting period. For most recent data, click the ownership history button. Values as filed, not updated for current price. Long positions only.

Financial report summary

Competition

Akorn • Staar Surgical • IRIDEX • Prestige Consumer Healthcare • EyePoint Pharmaceuticals • LENSAR • Albireo Pharma • Aerie Pharmaceuticals • Kiora Pharmaceuticals • Aquestive Therapeutics

Risks

As a result of the current conflict between Russia and Ukraine, including the recent invasion of Ukraine by Russia, the current and any future responses by the global community to such conflict and any counter responses by the Russian government or other entities or individuals, and the potential expansion of the conflict to other countries, we have begun to experience and may continue to experience an adverse impact on our business and operations in this region, as well as on our business and operations generally, which could have a material adverse effect on our business, financial condition, cash flows and results of operations and could cause the market value of our common shares to decline.

Management Discussion

Revenues for 2021 and 2020 were $8,434 million and $8,027 million, respectively, an increase of $407 million, or 5%. The increase was primarily driven by: (i) a net increase in volumes and (ii) the favorable impact of foreign currencies, primarily in Europe, Asia and Canada. These increases were partially offset by: (i) our divestiture of Amoun on July 26, 2021 and (ii) a decrease in net realized pricing. The net increase in volumes was primarily due to the positive impacts from the recovery from the COVID-19 pandemic and the easing of certain social restrictions, as previously discussed, primarily during the three months ended June 30, 2021, partially offset by the impact of the loss of exclusivity of certain products. The changes in our segment revenues and segment profits are discussed in further detail in the subsequent section titled “Reportable Segment Revenues and Profits”.

Content analysis

Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability	H.S. junior Avg

New words: abeyance, affiliate, agricultural, Apotex, banc, bankruptcy, benchmark, BLCO, bromide, buy, Cal, CDOR, cease, chapter, closer, CODM, commodity, community, conference, counter, counteractive, cyber, cybersecurity, cyberterrorism, Czech, damage, dealt, Dexamethasone, disconnect, discontent, displacement, divisional, doubt, Dutch, en, energy, EU, EURIBOR, exacerbating, facilitate, faith, fleeing, flexibility, Flunisolide, gas, gave, geopolitical, hampered, hepatology, hinder, hryvnia, humanitarian, IG, imposition, inadequate, inception, increasingly, installation, installment, Interntaional, invaded, invasion, Irish, irrevocably, JJCI, knowledge, Latanoprost, LIBOR, LTL, Lupin, mediate, mediation, Mellon, merger, methynaltrexone, military, network, notch, Notwithstanding, oil, omicron, overseeing, perpetrated, piped, popular, practice, precise, preclude, proactively, promptly, protracted, provoked, refundable, registration, rehearing, Remainco, repatriation, reply, Republic, retaliatory, ruble, Russia, Russian, satisfaction, Shanghai, shelter, sixty, skincare, Slovakia, SOFR, solicitation, Somerset, SONIA, StableVisc, sterling, stoppage, substantive, subvariant, surge, suspend, suspended, talc, taxation, thereunder, ticker, Tobramycin, traffic, trail, transitional, trustee, UK, Ukraine, Ukrainian, unavailability, underwriting, undrawn, unforeseen, Uniform, unrestricted, unwind, unwinding, unwound, vii, viii, voidable, war, Western, WHA, wholly, wider, worse, worsen

Removed: accessed, actinic, adenylate, Adjudication, Allegro, anemia, angiogenic, antihistamine, appointed, Appointment, ASS, atopic, bill, biopharmaceutical, Bisocard, bolt, bottom, BP, calculating, channel, classified, combined, commencement, complexity, compliant, consumption, Contrave, cyclase, defer, Departure, derivative, developing, Diastat, distributing, doctor, duty, Espaven, Eton, evidence, exceed, expanding, expensed, expensive, experiencing, exploring, FASB, fatty, feet, fiduciary, field, financed, forced, fumarate, funding, gradual, Graham, greatest, hiring, home, House, idling, impactful, implicated, initiation, insulated, integrin, interaction, intraperiod, Italy, Ivexterm, Jan, ketotifen, launching, led, Los, Luminate, measuring, metabolic, methodology, metric, Milan, minimizing, mitochondrial, moving, Mysimba, NAFLD, NASH, necessitate, NeutraSal, nonalcoholic, notably, operation, Ophtho, originated, performing, pituitary, postponement, postponing, preferred, prepay, preservative, prioritization, prioritize, privately, progressed, Prolensa, promoted, purportedly, readily, realigned, rebalancing, reenacting, relieve, remained, reopening, responded, retina, revising, risuteganib, room, separately, simultaneously, site, slower, spot, statue, steeper, Stockholder, targeting, thirty, Thrombo, translate, travel, unfavorably, University, VBP, Vice, warning, waste, yield

From filing 10-Q 2022 Q1

Financial reports

View all